Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response

• Published in: Vaccine Vol. 30; no. 39; pp. 5761 - 5769
• Main Authors: Taylor, David N., Treanor, John J., Sheldon, Eric A., Johnson, Casey, Umlauf, Scott, Song, Langzhou, Kavita, Uma, Liu, Ge, Tussey, Lynda, Ozer, Karen, Hofstaetter, Thomas, Shaw, Alan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 24.08.2012; Elsevier Limited
• Subjects: Adjuvants, Immunologic - administration & dosage; Adolescent; Adult; adults; Aged; Allergy and Immunology; Animals; Antibodies, Viral - blood; blood serum; Body temperature; C-reactive protein; C-Reactive Protein - immunology; C-Terminus; Clinical trials; Cytokines; Double-Blind Method; Female; Flagellin; Flagellin - immunology; Flagellin adjuvant; Frailty; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus - immunology; Hemagglutinins; Humans; Immune response; Immunogenicity; Influenza; Influenza prevention; Influenza vaccine; Influenza Vaccines - administration & dosage; Influenza Vaccines - adverse effects; Influenza Vaccines - immunology; Influenza, Human - prevention & control; Interleukin 6; Interleukin-6 - immunology; Laboratories; Male; Middle Aged; Rabbits; Recombinant vaccine; Seroconversion; Studies; temperature; Temperature effects; TLR5 protein; Toll-like receptors; Vaccine; Vaccines; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - adverse effects; Vaccines, Synthetic - immunology; Young Adult; Vaccine; Influenza prevention; Influenza vaccine; Flagellin adjuvant; Recombinant vaccine

► Recombinant influenza vaccines differ in safety profiles according to configuration. ► VAX128C was well tolerated up to a dose of 20μg. ► Dose of 1.25 or 2.5μg of VAX128C gave peak GMT was 385, 79% SC and 92% SP. We evaluated the safety and immunogenicity profiles of 3 novel influenza vaccine cons...